Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR NK-92 cells
- Development stage
- Preclinical
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR NK-92 cells is an allogeneic, gene-engineered cell therapy developed by Acıbadem Labcell. This therapy involves the NK-92 cell line that has been genetically engineered to express chimeric antigen receptors (CARs) designed to target tumor antigens. The NK-92 cell line is an activated natural killer cell line with high cytotoxicity against malignant cells. Acıbadem Labcell manufactures this as a cellular therapy service offering, with the cells expanded under GMP (Good Manufacturing Practice) conditions. The CAR-engineered NK-92 cells represent an allogeneic cell therapy approach that combines the innate cytotoxic properties of NK cells with the targeted specificity of CAR technology.
- Other names
- CAR NK92 CellsCAR-engineered NK92
02
Targets
CD19 (B lymphocyte antigen CD19)EBNA3C (EBV nuclear antigen 3C)CD226 (DNAX accessory molecule 1)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))ERBB2 (Erb-b2 receptor tyrosine kinase 2)NKG2D (Natural killer group 2 member D receptor)CD44v6 (CD44 variant isoform 6)LFA-1 (Integrin αLβ2)
Beyond the preview
Go deeper on CAR NK-92 cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR NK-92 cells.